{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:48:50Z","timestamp":1788241730810,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:00:00Z","timestamp":1579305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:00:00Z","timestamp":1579305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00702-019-02105-w","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T06:02:40Z","timestamp":1579327360000},"page":"843-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of tics associated with Tourette syndrome"],"prefix":"10.1007","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-4677","authenticated-orcid":false,"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,18]]},"reference":[{"key":"2105_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.prdoa.2019.11.005","volume":"2","author":"S Bellows","year":"2020","unstructured":"Bellows S, Jankovic J (2020) Treatment of dystonia and tics. Clin Parkinsonism Relat Disord 2:12\u201319","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"8","key":"2105_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","volume":"18","author":"H Bashir","year":"2018","unstructured":"Bashir H, Jankovic J (2018) Deutetrabenazine for the treatment of Huntington\u2019s chorea. Expert Rev Neurother 18(8):625\u2013631","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"2105_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jocrd.2014.03.005","volume":"3","author":"KJ Black","year":"2014","unstructured":"Black KJ, Jankovic J, Hershey T, McNaught KS, Mink JW, Walkup J (2014) Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord 3(4):359\u2013362","journal-title":"J Obsessive Compuls Relat Disord"},{"issue":"12","key":"2105_CR4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiat 6(12):995\u20131010","journal-title":"Lancet Psychiat"},{"issue":"4","key":"2105_CR5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jamaneurol.2018.4279","volume":"76","author":"G Brander","year":"2019","unstructured":"Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, Mataix-Cols D, Fern\u00e1ndez de la Cruz L (2019) Association of Tourette syndrome and chronic tic disorder with metabolic and cardiovascular disorders. JAMA Neurol 76(4):454\u2013461","journal-title":"JAMA Neurol"},{"issue":"3","key":"2105_CR6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU (2018) Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330\u2013340","journal-title":"World Psychiatry"},{"key":"2105_CR7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/B978-0-12-411546-0.00012-3","volume":"112","author":"AE Cavanna","year":"2013","unstructured":"Cavanna AE, Nani A (2013) Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol 112:373\u2013389","journal-title":"Int Rev Neurobiol"},{"issue":"7","key":"2105_CR8","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34(7):1487\u20131504","journal-title":"Clin Ther"},{"issue":"12","key":"2105_CR9","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/mds.21599","volume":"22","author":"MY Cheung","year":"2007","unstructured":"Cheung MY, Shahed J, Jankovic J (2007) Malignant Tourette syndrome. Mov Disord 22(12):1743\u20131750","journal-title":"Mov Disord"},{"issue":"2","key":"2105_CR10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3171\/2018.7.PEDS18300","volume":"23","author":"MA Coulombe","year":"2018","unstructured":"Coulombe MA, Elkaim LM, Alotaibi NM et al (2018) Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. J Neurosurg Pediatr 23(2):236\u2013246","journal-title":"J Neurosurg Pediatr"},{"key":"2105_CR11","first-page":"CD006565","volume":"4","author":"A Curtis","year":"2009","unstructured":"Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette\u2019s syndrome. Cochrane Database Syst Rev 4:CD006565","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"2105_CR12","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.cub.2014.08.038","volume":"24","author":"A Draper","year":"2014","unstructured":"Draper A, Stephenson MC, Jackson GM, P\u00e9p\u00e9s S, Morgan PS, Morris PG, Jackson SR (2014) Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol 24(19):2343\u20132347","journal-title":"Curr Biol"},{"issue":"9","key":"2105_CR13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"YS Du","year":"2008","unstructured":"Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB (2008) Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42(9):807\u2013813","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"2105_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","volume":"37","author":"DL Gilbert","year":"2014","unstructured":"Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (2014) A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 37(1):26\u201330","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"2105_CR15","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","volume":"33","author":"DL Gilbert","year":"2018","unstructured":"Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE (2018) Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord 33(8):1272\u20131280","journal-title":"Mov Disord"},{"issue":"13","key":"2105_CR16","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/bph.13243","volume":"173","author":"SC Godar","year":"2016","unstructured":"Godar SC, Mosher LJ, Strathman HJ et al (2016) The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement. Br J Pharmacol 173(13):2111\u20132121","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2105_CR17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pediatrneurol.2008.12.014","volume":"40","author":"EF Hedderick","year":"2009","unstructured":"Hedderick EF, Morris CM, Singer HS (2009) Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40(6):420\u2013425","journal-title":"Pediatr Neurol"},{"issue":"11","key":"2105_CR18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mds.26414","volume":"30","author":"J Jankovic","year":"2015","unstructured":"Jankovic J (2015) Therapeutic developments for tics and myoclonus. Mov Disord 30(11):1566\u20131573","journal-title":"Mov Disord"},{"issue":"18","key":"2105_CR19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"J Jankovic","year":"2016","unstructured":"Jankovic J (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 17(18):2461\u20132470","journal-title":"Expert Opin Pharmacother"},{"issue":"147","key":"2105_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","volume":"1","author":"J Jankovic","year":"2018","unstructured":"Jankovic J (2018) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 1(147):84\u201388","journal-title":"Toxicon"},{"issue":"1","key":"2105_CR21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW (2010) A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81(1):70\u201373","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2105_CR22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","volume":"7","author":"J Jankovic","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (2016) Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY) 7(6):422","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"issue":"20","key":"2105_CR23","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1021\/acs.jmedchem.8b01405","volume":"61","author":"M Jiang","year":"2018","unstructured":"Jiang M, van der Stelt M (2018) Activity-based protein profiling delivers selective drug candidate ABX-1431, a monoacylglycerol lipase inhibitor, to control lipid metabolism in neurological disorders. J Med Chem 61(20):9059\u20139061","journal-title":"J Med Chem"},{"issue":"6","key":"2105_CR24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(15)00008-3","volume":"14","author":"Z Kefalopoulou","year":"2015","unstructured":"Kefalopoulou Z, Zrinzo L, Jahanshahi M et al (2015) Bilateral globus pallidus stimulation for severe Tourette\u2019s syndrome: a double-blind, randomised crossover trial. Lancet Neurol 14(6):595\u2013605","journal-title":"Lancet Neurol"},{"key":"2105_CR25","first-page":"9","volume":"5","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Mejia N, Jankovic J (2007) Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol 5:9\u201313","journal-title":"J Ped Neurol"},{"issue":"10","key":"2105_CR26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40263-018-0559-8","volume":"32","author":"DD Kim","year":"2018","unstructured":"Kim DD, Barr AM, Chung Y et al (2018) Antipsychotic-associated symptoms of Tourette syndrome: a systematic review. CNS Drugs 32(10):917\u2013938","journal-title":"CNS Drugs"},{"issue":"3","key":"2105_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.26142","volume":"30","author":"B Kluger","year":"2015","unstructured":"Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313\u2013327","journal-title":"Mov Disord"},{"issue":"12","key":"2105_CR28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/mds.27860","volume":"34","author":"P Krack","year":"2019","unstructured":"Krack P, Volkmann J, Tinkhauser G, Deuschl G (2019) Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 34(12):1795\u20131810","journal-title":"Mov Disord"},{"issue":"5","key":"2105_CR29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/mds.870110512","volume":"11","author":"JK Krauss","year":"1996","unstructured":"Krauss JK, Jankovic J (1996) Severe motor tics causing cervical myelopathy in Tourette\u2019s syndrome. Mov Disord 11(5):563\u2013566","journal-title":"Mov Disord"},{"issue":"8","key":"2105_CR30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57(8):1190\u20131193","journal-title":"Arch Neurol"},{"issue":"12","key":"2105_CR31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/mds.10618","volume":"18","author":"C Kwak","year":"2003","unstructured":"Kwak C, Dat Vuong K, Jankovic J (2003) Premonitory sensory phenomenon in Tourette\u2019s syndrome. Mov Disord 18(12):1530\u20131533","journal-title":"Mov Disord"},{"issue":"Pt 6","key":"2105_CR32","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/brain\/aws104","volume":"135","author":"A Lerner","year":"2012","unstructured":"Lerner A, Bagic A, Simmons JM et al (2012) Widespread abnormality of the \u03b3-aminobutyric acid-ergic system in Tourette syndrome. Brain 135(Pt 6):1926\u20131936","journal-title":"Brain"},{"issue":"4","key":"2105_CR33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","volume":"15","author":"K Lim","year":"2017","unstructured":"Lim K, See YM, Lee J (2017) A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 15(4):301\u2013312","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"2105_CR34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-0035-1571217","volume":"36","author":"M Lotia","year":"2016","unstructured":"Lotia M, Jankovic J (2016) Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol 36(1):54\u201363","journal-title":"Semin Neurol"},{"issue":"5","key":"2105_CR35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE (2001) Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56(5):605\u2013610","journal-title":"Neurology"},{"issue":"3","key":"2105_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","volume":"75","author":"D Martinez-Ramirez","year":"2018","unstructured":"Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF et al (2018) Efficacy and safety of deep brain stimulation in tourette syndrome: the international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol 75(3):353\u2013359","journal-title":"JAMA Neurol"},{"key":"2105_CR37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/B978-0-12-411546-0.00010-X","volume":"112","author":"S Mogwitz","year":"2013","unstructured":"Mogwitz S, Buse J, Ehrlich S, Roessner V (2013) Clinical pharmacology of dopamine-modulating agents in Tourette\u2019s syndrome. Int Rev Neurobiol 112:281\u2013349","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"2105_CR38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/294264","volume":"27","author":"KR M\u00fcller-Vahl","year":"2013","unstructured":"M\u00fcller-Vahl KR (2013) Treatment of Tourette syndrome with cannabinoids. Behav Neurol 27(1):119\u2013124","journal-title":"Behav Neurol"},{"issue":"1","key":"2105_CR39","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41598-018-37710-4","volume":"9","author":"KR M\u00fcller-Vahl","year":"2019","unstructured":"M\u00fcller-Vahl KR, Szejko N, Wilke F, Jakubovski E, Geworski L, Bengel F, Berding G (2019) Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. Sci Rep 9(1):972","journal-title":"Sci Rep"},{"issue":"9","key":"2105_CR40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","volume":"27","author":"TK Murphy","year":"2017","unstructured":"Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L (2017) Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 27(9):762\u2013770","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"2105_CR41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-018-0874-x","volume":"78","author":"N Niemann","year":"2018","unstructured":"Niemann N, Jankovic J (2018) Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 78(5):525\u2013541","journal-title":"Drugs"},{"issue":"3","key":"2105_CR42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/NRL.0000000000000218","volume":"24","author":"S Pandey","year":"2019","unstructured":"Pandey S, Dash D (2019) Progress in Pharmacological and surgical management of Tourette syndrome and other chronic Tic disorders. Neurologist 24(3):93\u2013108","journal-title":"Neurologist"},{"key":"2105_CR43","first-page":"CD012285","volume":"1","author":"S Pandey","year":"2018","unstructured":"Pandey S, Srivanitchapoom P, Kirubakaran R, Berman BD (2018) Botulinum toxin for motor and phonic tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev 1:CD012285","journal-title":"Cochrane Database Syst Rev"},{"key":"2105_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-411546-0.00006-8","volume":"112","author":"P Paschou","year":"2013","unstructured":"Paschou P, Fernandez TV, Sharp F, Heiman GA, Hoekstra PJ (2013) Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol 112:155\u2013177","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"2105_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.23402","volume":"26","author":"MS Pe\u00f1a","year":"2011","unstructured":"Pe\u00f1a MS, Yaltho TC, Jankovic J (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26(1):147\u2013152","journal-title":"Mov Disord"},{"issue":"6","key":"2105_CR46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","volume":"24","author":"M Porta","year":"2004","unstructured":"Porta M, Maggioni G, Ottaviani F, Schindler A (2004) Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A. Neurol Sci 24(6):420\u2013423","journal-title":"Neurol Sci"},{"issue":"19","key":"2105_CR47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, M\u00fcller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019a) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):907\u2013915","journal-title":"Neurology"},{"issue":"19","key":"2105_CR48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019b) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896\u2013906","journal-title":"Neurology"},{"issue":"1","key":"2105_CR49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-017-0486-0","volume":"32","author":"J Quezada","year":"2018","unstructured":"Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs 32(1):33\u201345","journal-title":"CNS Drugs"},{"key":"2105_CR50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fpsyt.2018.00100","volume":"9","author":"R Rizzo","year":"2018","unstructured":"Rizzo R, Pellico A, Silvestri PR et al (2018) A randomized controlled trial comparing behavioral, educational, and pharmacological treatments in youths with chronic Tic disorder or Tourette syndrome. Front Psychiatry 9:100","journal-title":"Front Psychiatry"},{"key":"2105_CR51","doi-asserted-by":"crossref","first-page":"16097","DOI":"10.1038\/nrdp.2016.97","volume":"3","author":"MM Robertson","year":"2017","unstructured":"Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, Roessner V, Woods DW, Hariz M, Mathews CA, \u010crn\u010dec R, Leckman JF (2017) Gilles de la Tourette syndrome. Nat Rev Dis Prime 3:16097","journal-title":"Nat Rev Dis Prime"},{"key":"2105_CR52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","volume":"68","author":"V Roessner","year":"2013","unstructured":"Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, M\u00fcnchau A (2013) Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology 68:143\u2013149","journal-title":"Neuropharmacology"},{"key":"2105_CR53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/17460441.2018.1394838","volume":"13","author":"ZT Sahli","year":"2018","unstructured":"Sahli ZT, Tarazi FI (2018) Pimavanserin: novel pharmacotherapy for Parkinson\u2019s disease psychosis. Expert Opin Drug Discov 13:103\u2013110","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"2105_CR54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27(9):771\u2013781","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"2105_CR55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/cns.12789","volume":"24","author":"A Santangelo","year":"2018","unstructured":"Santangelo A, Bortolato M, Mosher LJ, Crescimanno G, Di Giovanni G, Cassioli E, Ricca V, Casarrubea M (2018) Behavioral fragmentation in the D1CT-7 mouse model of Tourette\u2019s syndrome. CNS Neurosci Ther 24(8):703\u2013711","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"2105_CR56","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","volume":"91","author":"JL Schultz","year":"2018","unstructured":"Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA (2018) Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology 91(3):e202\u2013e207","journal-title":"Neurology"},{"issue":"4","key":"2105_CR57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870110413","volume":"11","author":"BL Scott","year":"1996","unstructured":"Scott BL, Jankovic J, Donovan DT (1996) Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette\u2019s syndrome. Mov Disord 11(4):431\u2013433","journal-title":"Mov Disord"},{"key":"2105_CR58","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7424.1","author":"MA Thenganatt","year":"2016","unstructured":"Thenganatt MA, Jankovic J (2016) Recent advances in understanding and managing Tourette syndrome. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.7424.1","journal-title":"F1000Res"},{"issue":"4","key":"2105_CR59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.v66n0413","volume":"66","author":"P Toren","year":"2005","unstructured":"Toren P, Weizman A, Ratner S, Cohen D, Laor N (2005) Ondansetron treatment in Tourette\u2019s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 66(4):499\u2013503","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2105_CR60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"Tourette\u2019s Syndrome Study Group","year":"2002","unstructured":"Tourette\u2019s Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4):527\u2013536","journal-title":"Neurology"},{"issue":"4","key":"2105_CR61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000337776","volume":"90","author":"A Viswanathan","year":"2012","unstructured":"Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J (2012) Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 90(4):213\u2013224","journal-title":"Stereotact Funct Neurosurg"},{"issue":"6","key":"2105_CR62","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","volume":"37","author":"H Weisman","year":"2013","unstructured":"Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH (2013) Systematic review: pharmacological treatment of tic disorders\u2013efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 37(6):1162\u20131171","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"2105_CR63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.25692","volume":"29","author":"S Wijemanne","year":"2014","unstructured":"Wijemanne S, Wu LJ, Jankovic J (2014) Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 29(1):126\u2013130","journal-title":"Mov Disord"},{"issue":"5","key":"2105_CR64","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pediatrneurol.2013.05.002","volume":"49","author":"CS Yang","year":"2013","unstructured":"Yang CS, Zhang LL, Zeng LN, Huang L, Liu YT (2013) Topiramate for Tourette\u2019s syndrome in children: a meta-analysis. Pediatr Neurol 49(5):344\u2013350","journal-title":"Pediatr Neurol"},{"issue":"8","key":"2105_CR65","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry 74(8):e772\u2013e780","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02105-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T19:24:09Z","timestamp":1614021849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02105-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,18]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02105-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,18]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}